-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, May 14 News On May 12, Bayer Group has a good start in the 2021 fiscal year.
"Our overall operating performance is good, but it has been affected by the expected adverse exchange rate.
" CEO Werner Baumann said in the release of the quarterly report for the first quarter of fiscal 2021 on Wednesday.
"Our The Crop Science Division has achieved exciting sales growth in an improved market environment.
Sales of the Prescription Drug Division have remained stable, and our Consumer Health Products Division has led the industry in performance.
"
"Our overall operating performance is good, but it has been affected by the expected adverse exchange rate.
" CEO Werner Baumann said in the release of the quarterly report for the first quarter of fiscal 2021 on Wednesday.
"Our The Crop Science Division has achieved exciting sales growth in an improved market environment.
Sales of the Prescription Drug Division have remained stable, and our Consumer Health Products Division has led the industry in performance.
"
Bayer Group’s sales in the first quarter increased by 2.
8% (adjusted for exchange rates and asset mix) to 12.
328 billion euros.
Net income increased by 40.
3% to 2.
089 billion euros.
8% (adjusted for exchange rates and asset mix) to 12.
328 billion euros.
Net income increased by 40.
3% to 2.
089 billion euros.
Bayer's agricultural business (Crop Science Division) sales increased by 6.
4% (adjusted by exchange rate and asset portfolio) to 6.
646 billion euros, with growth in Latin America and the Asia-Pacific region being particularly strong.
The sales of the herbicide business increased strongly by 13.
3%, and the sales of the fungicide business (increased by 22.
0%) and the vegetable seed business (increased by 13.
9%) also increased significantly.
Sales of the vegetable seed business achieved growth in all regions.
The sales of soybean seeds and traits business increased by 3.
4% (adjusted for exchange rate and asset mix), benefited from sales growth in North America.
4% (adjusted by exchange rate and asset portfolio) to 6.
646 billion euros, with growth in Latin America and the Asia-Pacific region being particularly strong.
The sales of the herbicide business increased strongly by 13.
3%, and the sales of the fungicide business (increased by 22.
0%) and the vegetable seed business (increased by 13.
9%) also increased significantly.
Sales of the vegetable seed business achieved growth in all regions.
The sales of soybean seeds and traits business increased by 3.
4% (adjusted for exchange rate and asset mix), benefited from sales growth in North America.
Sales of the prescription drug business (prescription drug division) were 4.
365 billion euros, the same as the same period last year.
365 billion euros, the same as the same period last year.
The Consumer Health Products Division led the industry in performance, and experienced cyclical fluctuations after achieving strong growth in the first quarter of last year.
The performance of the Consumer Health Products Division continued to lead the industry.
The growth momentum was mainly derived from the skin and nutrition categories.
Sales increased by 6.
6% and 4.
7% respectively (adjusted by exchange rate and asset portfolio).
However, continued strict protection and sanitation measures and blockade policies have also had a negative impact on sales, especially cough and cold products.
Sales revenues in the Asia-Pacific and Latin America regions continued to grow positively, while sales revenues in North America and Europe/Middle East/Africa were obviously affected by particularly mild over-sensitive off-season effects.
The performance of the Consumer Health Products Division continued to lead the industry.
The growth momentum was mainly derived from the skin and nutrition categories.
Sales increased by 6.
6% and 4.
7% respectively (adjusted by exchange rate and asset portfolio).
However, continued strict protection and sanitation measures and blockade policies have also had a negative impact on sales, especially cough and cold products.
Sales revenues in the Asia-Pacific and Latin America regions continued to grow positively, while sales revenues in North America and Europe/Middle East/Africa were obviously affected by particularly mild over-sensitive off-season effects.
Bayer also made good progress in the field of sustainable development in the first quarter.
As announced in February, the company is currently stepping up the implementation of a more inclusive and diversified employee structure and corporate culture.
The goal is to achieve a gender balance in all management positions by 2030.
Also in February, the Consumer Health Products Division also launched a "Nutrition Supplement Plan" aimed at providing vitamins and minerals to people in underdeveloped areas and narrowing the gap in their access to nutritional supplements.
The project plans to reach 50 million people in underdeveloped areas every year by 2030 through direct assistance and cooperation with major non-governmental organizations (NGOs).
The "Nutrition Supplement Plan" helps achieve the sustainable development goal of the Consumer Health Products Business Unit, which is to provide daily health care services to 100 million people in underdeveloped areas by 2030 .
As announced in February, the company is currently stepping up the implementation of a more inclusive and diversified employee structure and corporate culture.
The goal is to achieve a gender balance in all management positions by 2030.
Also in February, the Consumer Health Products Division also launched a "Nutrition Supplement Plan" aimed at providing vitamins and minerals to people in underdeveloped areas and narrowing the gap in their access to nutritional supplements.
The project plans to reach 50 million people in underdeveloped areas every year by 2030 through direct assistance and cooperation with major non-governmental organizations (NGOs).
The "Nutrition Supplement Plan" helps achieve the sustainable development goal of the Consumer Health Products Business Unit, which is to provide daily health care services to 100 million people in underdeveloped areas by 2030 .
Medical Network, May 14 News On May 12, Bayer Group has a good start in the 2021 fiscal year.
"Our overall operating performance is good, but it has been affected by the expected adverse exchange rate.
" CEO Werner Baumann said in the release of the quarterly report for the first quarter of fiscal 2021 on Wednesday.
"Our The Crop Science Division has achieved exciting sales growth in an improved market environment.
Sales of the Prescription Drug Division have remained stable, and our Consumer Health Products Division has led the industry in performance.
"
"Our overall operating performance is good, but it has been affected by the expected adverse exchange rate.
" CEO Werner Baumann said in the release of the quarterly report for the first quarter of fiscal 2021 on Wednesday.
"Our The Crop Science Division has achieved exciting sales growth in an improved market environment.
Sales of the Prescription Drug Division have remained stable, and our Consumer Health Products Division has led the industry in performance.
"
Bayer Group’s sales in the first quarter increased by 2.
8% (adjusted for exchange rates and asset mix) to 12.
328 billion euros.
Net income increased by 40.
3% to 2.
089 billion euros.
8% (adjusted for exchange rates and asset mix) to 12.
328 billion euros.
Net income increased by 40.
3% to 2.
089 billion euros.
Bayer's agricultural business (Crop Science Division) sales increased by 6.
4% (adjusted by exchange rate and asset portfolio) to 6.
646 billion euros, with growth in Latin America and the Asia-Pacific region being particularly strong.
The sales of the herbicide business increased strongly by 13.
3%, and the sales of the fungicide business (increased by 22.
0%) and the vegetable seed business (increased by 13.
9%) also increased significantly.
Sales of the vegetable seed business achieved growth in all regions.
The sales of soybean seeds and traits business increased by 3.
4% (adjusted for exchange rate and asset mix), benefited from sales growth in North America.
4% (adjusted by exchange rate and asset portfolio) to 6.
646 billion euros, with growth in Latin America and the Asia-Pacific region being particularly strong.
The sales of the herbicide business increased strongly by 13.
3%, and the sales of the fungicide business (increased by 22.
0%) and the vegetable seed business (increased by 13.
9%) also increased significantly.
Sales of the vegetable seed business achieved growth in all regions.
The sales of soybean seeds and traits business increased by 3.
4% (adjusted for exchange rate and asset mix), benefited from sales growth in North America.
Sales of the prescription drug business (prescription drug division) were 4.
365 billion euros, the same as the same period last year.
365 billion euros, the same as the same period last year.
The Consumer Health Products Division led the industry in performance, and experienced cyclical fluctuations after achieving strong growth in the first quarter of last year.
The performance of the Consumer Health Products Division continued to lead the industry.
The growth momentum was mainly derived from the skin and nutrition categories.
Sales increased by 6.
6% and 4.
7% respectively (adjusted by exchange rate and asset portfolio).
However, continued strict protection and sanitation measures and blockade policies have also had a negative impact on sales, especially cough and cold products.
Sales revenues in the Asia-Pacific and Latin America regions continued to grow positively, while sales revenues in North America and Europe/Middle East/Africa were obviously affected by particularly mild over-sensitive off-season effects.
The performance of the Consumer Health Products Division continued to lead the industry.
The growth momentum was mainly derived from the skin and nutrition categories.
Sales increased by 6.
6% and 4.
7% respectively (adjusted by exchange rate and asset portfolio).
However, continued strict protection and sanitation measures and blockade policies have also had a negative impact on sales, especially cough and cold products.
Sales revenues in the Asia-Pacific and Latin America regions continued to grow positively, while sales revenues in North America and Europe/Middle East/Africa were obviously affected by particularly mild over-sensitive off-season effects.
Bayer also made good progress in the field of sustainable development in the first quarter.
As announced in February, the company is currently stepping up the implementation of a more inclusive and diversified employee structure and corporate culture.
The goal is to achieve a gender balance in all management positions by 2030.
Also in February, the Consumer Health Products Division also launched a "Nutrition Supplement Plan" aimed at providing vitamins and minerals to people in underdeveloped areas and narrowing the gap in their access to nutritional supplements.
The project plans to reach 50 million people in underdeveloped areas every year by 2030 through direct assistance and cooperation with major non-governmental organizations (NGOs).
The "Nutrition Supplement Plan" helps achieve the sustainable development goal of the Consumer Health Products Business Unit, which is to provide daily health care services to 100 million people in underdeveloped areas by 2030 .
As announced in February, the company is currently stepping up the implementation of a more inclusive and diversified employee structure and corporate culture.
The goal is to achieve a gender balance in all management positions by 2030.
Also in February, the Consumer Health Products Division also launched a "Nutrition Supplement Plan" aimed at providing vitamins and minerals to people in underdeveloped areas and narrowing the gap in their access to nutritional supplements.
The project plans to reach 50 million people in underdeveloped areas every year by 2030 through direct assistance and cooperation with major non-governmental organizations (NGOs).
The "Nutrition Supplement Plan" helps achieve the sustainable development goal of the Consumer Health Products Business Unit, which is to provide daily health care services to 100 million people in underdeveloped areas by 2030 .
Medical Network, May 14 News On May 12, Bayer Group has a good start in the 2021 fiscal year.
"Our overall operating performance is good, but it has been affected by the expected adverse exchange rate.
" CEO Werner Baumann said in the release of the quarterly report for the first quarter of fiscal 2021 on Wednesday.
"Our The Crop Science Division has achieved exciting sales growth in an improved market environment.
Sales of the Prescription Drug Division have remained stable, and our Consumer Health Products Division has led the industry in performance.
"
"Our overall operating performance is good, but it has been affected by the expected adverse exchange rate.
" CEO Werner Baumann said in the release of the quarterly report for the first quarter of fiscal 2021 on Wednesday.
"Our The Crop Science Division has achieved exciting sales growth in an improved market environment.
Sales of the Prescription Drug Division have remained stable, and our Consumer Health Products Division has led the industry in performance.
"
Bayer Group’s sales in the first quarter increased by 2.
8% (adjusted for exchange rates and asset mix) to 12.
328 billion euros.
Net income increased by 40.
3% to 2.
089 billion euros.
8% (adjusted for exchange rates and asset mix) to 12.
328 billion euros.
Net income increased by 40.
3% to 2.
089 billion euros.
Bayer's agricultural business (Crop Science Division) sales increased by 6.
4% (adjusted by exchange rate and asset portfolio) to 6.
646 billion euros, with growth in Latin America and the Asia-Pacific region being particularly strong.
The sales of the herbicide business increased strongly by 13.
3%, and the sales of the fungicide business (increased by 22.
0%) and the vegetable seed business (increased by 13.
9%) also increased significantly.
Sales of the vegetable seed business achieved growth in all regions.
The sales of soybean seeds and traits business increased by 3.
4% (adjusted for exchange rate and asset mix), benefited from sales growth in North America.
4% (adjusted by exchange rate and asset portfolio) to 6.
646 billion euros, with growth in Latin America and the Asia-Pacific region being particularly strong.
The sales of the herbicide business increased strongly by 13.
3%, and the sales of the fungicide business (increased by 22.
0%) and the vegetable seed business (increased by 13.
9%) also increased significantly.
Sales of the vegetable seed business achieved growth in all regions.
The sales of soybean seeds and traits business increased by 3.
4% (adjusted for exchange rate and asset mix), benefited from sales growth in North America.
Sales of the prescription drug business (prescription drug division) were 4.
365 billion euros, the same as the same period last year.
365 billion euros, the same as the same period last year.
The Consumer Health Products Division led the industry in performance, and experienced cyclical fluctuations after achieving strong growth in the first quarter of last year.
The performance of the Consumer Health Products Division continued to lead the industry.
The growth momentum was mainly derived from the skin and nutrition categories.
Sales increased by 6.
6% and 4.
7% respectively (adjusted by exchange rate and asset portfolio).
However, continued strict protection and sanitation measures and blockade policies have also had a negative impact on sales, especially cough and cold products.
Sales revenues in the Asia-Pacific and Latin America regions continued to grow positively, while sales revenues in North America and Europe/Middle East/Africa were obviously affected by particularly mild over-sensitive off-season effects.
The performance of the Consumer Health Products Division continued to lead the industry.
The growth momentum was mainly derived from the skin and nutrition categories.
Sales increased by 6.
6% and 4.
7% respectively (adjusted by exchange rate and asset portfolio).
However, continued strict protection and sanitation measures and blockade policies have also had a negative impact on sales, especially cough and cold products.
Sales revenues in the Asia-Pacific and Latin America regions continued to grow positively, while sales revenues in North America and Europe/Middle East/Africa were obviously affected by particularly mild over-sensitive off-season effects.
Bayer also made good progress in the field of sustainable development in the first quarter.
As announced in February, the company is currently stepping up the implementation of a more inclusive and diversified employee structure and corporate culture.
The goal is to achieve a gender balance in all management positions by 2030.
Also in February, the Consumer Health Products Division also launched a "Nutrition Supplement Plan" aimed at providing vitamins and minerals to people in underdeveloped areas and narrowing the gap in their access to nutritional supplements.
The project plans to reach 50 million people in underdeveloped areas every year by 2030 through direct assistance and cooperation with major non-governmental organizations (NGOs).
The "Nutrition Supplement Plan" helps achieve the sustainable development goal of the Consumer Health Products Business Unit, which is to provide daily health care services to 100 million people in underdeveloped areas by 2030 .
Enterprise Enterprise Enterprise Health Health Health Health Care Health Care As announced in February, the company is currently stepping up the implementation of a more inclusive and diversified employee structure and corporate culture.
The goal is to achieve a gender balance in all management positions by 2030.
Also in February, the Consumer Health Products Division also launched a "Nutrition Supplement Plan" aimed at providing vitamins and minerals to people in underdeveloped areas and narrowing the gap in their access to nutritional supplements.
The project plans to reach 50 million people in underdeveloped areas every year by 2030 through direct assistance and cooperation with major non-governmental organizations (NGOs).
The "Nutrition Supplement Plan" helps achieve the sustainable development goal of the Consumer Health Products Business Unit, which is to provide daily health care services to 100 million people in underdeveloped areas by 2030 .
